Leerink Partnrs Issues Positive Estimate for DexCom Earnings

DexCom, Inc. (NASDAQ:DXCM) – Investment analysts at Leerink Partnrs boosted their Q1 2025 earnings estimates for DexCom in a research note issued on Friday, February 14th. Leerink Partnrs analyst M. Kratky now forecasts that the medical device company will post earnings per share of $0.31 for the quarter, up from their prior estimate of $0.30. The consensus estimate for DexCom’s current full-year earnings is $1.69 per share. Leerink Partnrs also issued estimates for DexCom’s Q2 2025 earnings at $0.51 EPS and FY2029 earnings at $3.67 EPS.

Other research analysts also recently issued reports about the company. Raymond James cut their price objective on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th. Sanford C. Bernstein boosted their price target on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Leerink Partners reduced their price objective on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Morgan Stanley lifted their price objective on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday. Finally, Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and upped their target price for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and an average price target of $99.06.

DexCom Stock Performance

NASDAQ:DXCM opened at $89.07 on Monday. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The company has a market capitalization of $34.79 billion, a P/E ratio of 53.34, a price-to-earnings-growth ratio of 2.26 and a beta of 1.14. The firm has a 50-day moving average price of $82.44 and a two-hundred day moving average price of $75.49. DexCom has a twelve month low of $62.34 and a twelve month high of $142.00.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 31.40% and a net margin of 17.22%.

Institutional Trading of DexCom

Several large investors have recently added to or reduced their stakes in the stock. Forvis Mazars Wealth Advisors LLC grew its stake in shares of DexCom by 0.7% in the fourth quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company’s stock valued at $1,359,000 after buying an additional 118 shares in the last quarter. Principal Securities Inc. grew its position in DexCom by 3.4% in the fourth quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company’s stock valued at $316,000 after acquiring an additional 135 shares in the last quarter. Larson Financial Group LLC raised its stake in shares of DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 137 shares during the period. Level Four Advisory Services LLC lifted its position in shares of DexCom by 1.1% during the fourth quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company’s stock worth $1,026,000 after purchasing an additional 150 shares in the last quarter. Finally, Covestor Ltd boosted its stake in shares of DexCom by 15.6% in the fourth quarter. Covestor Ltd now owns 1,109 shares of the medical device company’s stock valued at $86,000 after purchasing an additional 150 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at DexCom

In related news, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 42,342 shares of company stock worth $3,628,069 in the last ninety days. Insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.